Okay, the way it worked was that the provinces agreed there would be a joint oncology review. Ontario offered to have their drug review serve as the basis for that joint initiative. Since that time, British Columbia has also joined the initiative, because we felt that the information coming from the joint oncology review could inform the process for the B.C. Cancer Agency as well as it would in other parts of the country.
I'm not sure if that answers your question sufficiently or if I've misinterpreted the question.